Mbx Biosciences Inc (MBX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MBX quarterly Cash Flow →
Looking at cash flow data from Mbx Biosciences Inc through provides insight into Dec 31 2025's financial flexibility across reporting periods.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024)
Operating Activities
Income-86.97
Depreciation & amortization0.25
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation8.68
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Operating Lease Expense0.13
Increase Decrease In Operating Lease Liability0.43
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-2.46
Increase (Decrease) in Accrued Liabilities6.80
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.70
Other Working Capital0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.11
Discontinued operations0.00
Net Cash flow from Operating Activities-79.95
Investing Activities
Capital Expenditures-1.93
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities267.87
Payments to Acquire Marketable Securities-358.15
Real Estate Investments0.00
Proceeds From Call Redemptions Of Marketable Securities8.50
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-83.71
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.64
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Preferred Stock Issuance Costs-
Proceeds From Issuance Public Offering187.95
Proceeds From Issuance At- The- Market Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities189.59
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-81.88
Total Cash Flow25.94
4 historic quarters locked

Sign in to unlock the full Mbx Biosciences Inc cash flow history.

About Mbx Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 12, 2026
  • Source: mbx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-103121

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License